Neurocrine Biosciences Stock (NASDAQ: NBIX)

Neurocrine Biosciences (NASDAQ:NBIX) Stock

Neurocrine Biosciences

Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.

paypal-shutter2

Equities

Large Cap

News

Movers

Trading Ideas

AVTR

ILMN

MRNA

NBIX

PYPL

SWKS

Skyworks Solutions, Estee Lauder, Venture Global, Neurocrine Biosciences, Moderna, Illumina, IDEX Corporation, PTC Inc, PayPal Holdings, Skechers U.S.A. and Avantor were worst performers, fell up to 25%.

Estee Lauder, Moderna And PayPal Are Among Top 10 Large Cap Losers Last Week (Feb 3-Feb 7): Are The Others In Your Portfolio?

Analyst Color

Biotech

Earnings

Guidance

Health Care

Analyst Ratings

General

Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza&#39;s long-term growth despite near-term challenges.

Why Is Neurocrine Biosciences Stock Trading Lower On Friday?

Contracts

Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal.

Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences Inc

WIIM

Neurocrine Biosciences shares are trading higher after the company authorized a $500 million share repurchase program.

Analysts' ratings for Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) over the last quarter vary from bullish to bearish, as provided by 15 analysts.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $169.4, with a high estimate of $190.00 and a low estimate of $147.00. This current average reflects an increase of 0.47% from the previous average price target of $168.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1740146453_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Neurocrine Biosciences among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$185.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Yatin Suneja</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$163.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$185.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$148.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$147.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$163.00</td>
<td>$172.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$185.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$179.00</td>
<td>$184.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$176.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$162.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>David Amsellem</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$165.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Laura Chico</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$148.00</td>
<td>$148.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Neurocrine Biosciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Neurocrine Biosciences compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Neurocrine Biosciences's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Neurocrine Biosciences's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NBIX/analyst-ratings?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Neurocrine Biosciences analyst ratings.</a>
<h2>Delving into Neurocrine Biosciences's Background</h2>
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
<h3>Understanding the Numbers: Neurocrine Biosciences's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Neurocrine Biosciences's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 21.84%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Neurocrine Biosciences's net margin excels beyond industry benchmarks, reaching 16.43%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Neurocrine Biosciences's ROE excels beyond industry benchmarks, reaching 3.88%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Neurocrine Biosciences's ROA excels beyond industry benchmarks, reaching 2.84%. This signifies efficient management of assets and strong financial health.
Debt Management: Neurocrine Biosciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.18.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Neurocrine Biosciences: Insights From 15 Financial Analysts

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and maintains $185 price target.

Price Target

Reiteration

HC Wainwright & Co. Reiterates Buy on Neurocrine Biosciences, Maintains $185 Price Target

Neurocrine Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) today announced that its Board of&nbsp;Directors has authorized a&nbsp;new share&nbsp;repurchase&nbsp;program under which Neurocrine Biosciences may repurchase up to $500 million of its shares, subject to market conditions. This new share repurchase authorization is in addition to the $300 million accelerated repurchase program that was announced in October 2024 and completed in early February 2025.

Buybacks

Neurocrine Biosciences Authorizes $500M Share Repurchase Program; This New Share Repurchase Authorization Is In Addition To The $300M Accelerated Repurchase Program That Was Announced In October 2024 And Completed In Early February 2025

Neurocrine Biosciences shares are trading lower after HC Wainwright & Co. and Guggenheim cut their respective price targets on the stock.

Guggenheim analyst Yatin Suneja maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and lowers the price target from $165 to $163.

Guggenheim Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $163

HC Wainwright &amp; Co. analyst Andrew Fein maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and lowers the price target from $190 to $185.

HC Wainwright & Co. Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $185

These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>Skyworks Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWKS#NASDAQ">SWKS</a>) stock declined 25.99% after the company reported first-quarter earnings and issued second-quarter guidance below estimates. Analysts revised <a href="https://www.benzinga.com//node/43540329" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>Estee Lauder Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) stock plummeted 22.05%  after the company <a href="https://www.benzinga.com//node/43462736" target="_blank" rel="noreferrer noopener">reported second-quarter results</a>. Several analysts lowered <a href="https://www.benzinga.com/quote/el/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>Neurocrine Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) shares tumbled 19.23% after the company missed its fourth-quarter revenue <a href="https://www.benzinga.com//node/43544393" target="_blank" rel="noreferrer noopener">estimate when reporting financial results</a>. Additionally, HC Wainwright &amp; Co. and B of A Securities lowered <a href="https://www.benzinga.com/quote/nbix/analyst-ratings" target="_blank" rel="noreferrer noopener">their respective price forecasts on the stock</a>.</li>
<li>Moderna, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) shares fell 17.30%, probably after the Senate Finance Committee voted to advance Robert F. Kennedy Jr.&#8217;s nomination to the Senate floor.</li>
<li>Illumina, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) stock was down 16.33% after the company <a href="https://www.benzinga.com//node/43544682" target="_blank" rel="noreferrer noopener">reported fourth-quarter results</a>. Analysts lowered <a href="https://www.benzinga.com/quote/ilmn/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>Venture Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VG#NYSE">VG</a>) stock decreased 14.23%, probably after President Trump reiterated a pledge to increase oil production.</li>
<li>Avantor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) shares declined 14.01% after the company reported fourth-quarter results and <a href="https://www.benzinga.com//node/43560312" target="_blank" rel="noreferrer noopener">missed its adjusted EPS estimate</a>.</li>
<li>PayPal Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PYPL#NASDAQ">PYPL</a>) stock tumbled 12.72% after the company reported fourth-quarter results and analysts <a href="https://www.benzinga.com//node/43475080" target="_blank" rel="noreferrer noopener">revised the price forecast</a>.</li>
<li>IDEX Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IEX#NYSE">IEX</a>) shares fell 12.65% following mixed <a href="https://www.benzinga.com//node/43479651" target="_blank" rel="noreferrer noopener">fourth-quarter financial results</a>. Analysts revised <a href="https://www.benzinga.com/quote/iex/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>PTC Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTC#NASDAQ">PTC</a>) shares declined 12.64% after the company reported first-quarter financial results, issued guidance below <a href="https://www.benzinga.com//node/43509190" target="_blank" rel="noreferrer noopener">estimates and cut its FY25 guidance</a>.</li>
</ol>
Photo by Lets Design Studio via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/02/43580845/palantir-super-micro-computer-and-spotify-are-among-top-10-large-cap-gainers-last-week-feb-3-feb-7-are-the-others-in-your-portfolio" target="_blank" rel="noreferrer noopener">Palantir, Super Micro Computer And Spotify Are Among Top 10 Large Cap Gainers Last Week (Feb 3-Feb 7): Are The Others In Your Portfolio?</a></li>
</ul>

<h3>Gainers</h3>
<ul>
<li>Cyclo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTH#NASDAQ">CYTH</a>) shares rose 74.0% to $1.34 during Friday's pre-market session. The market value of their outstanding shares is at $43.8 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares increased by 73.54% to $2.69. The market value of their outstanding shares is at $4.1 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock rose 31.55% to $0.21. The market value of their outstanding shares is at $1.8 million. </li>
<li>Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) shares moved upwards by 23.48% to $71.94. The market value of their outstanding shares is at $13.4 billion. The company's, Q3 earnings came out yesterday. </li>
<li>enVVeno Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVNO#NASDAQ">NVNO</a>) stock rose 13.18% to $3.52. The market value of their outstanding shares is at $61.7 million. </li>
<li>Nanobiotix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBTX#NASDAQ">NBTX</a>) shares moved upwards by 12.78% to $3.97. The market value of their outstanding shares is at $188.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Fractyl Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GUTS#NASDAQ">GUTS</a>) shares declined by 24.2% to $1.22 during Friday's pre-market session. The market value of their outstanding shares is at $58.6 million. </li>
<li>Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) shares declined by 17.3% to $5.45. The company's market cap stands at $296.5 million. </li>
<li>Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) shares decreased by 16.15% to $126.21. The market value of their outstanding shares is at $12.7 billion. The company's, Q4 earnings came out yesterday. </li>
<li>Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) stock decreased by 14.9% to $3.03. The company's market cap stands at $168.6 million. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) shares decreased by 13.57% to $9.94. The company's market cap stands at $30.2 million. </li>
<li>RenovoRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNXT#NASDAQ">RNXT</a>) shares fell 13.02% to $1.27. The market value of their outstanding shares is at $30.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALMS

CYTH

DOCS

GUTS

NBTX

NVNO

RNXT

STIM

XCUR

12 Health Care Stocks Moving In Friday's Pre-Market Session

RBC Capital analyst Brian Abrahams maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Sector Perform and lowers the price target from $154 to $148.

RBC Capital Maintains Sector Perform on Neurocrine Biosciences, Lowers Price Target to $148

Wedbush analyst Laura Chico maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Outperform and lowers the price target from $157 to $147.

Wedbush Maintains Outperform on Neurocrine Biosciences, Lowers Price Target to $147

Canaccord Genuity analyst Sumant Kulkarni maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and lowers the price target from $172 to $163.

Canaccord Genuity Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $163

On Thursday, Neurocrine Biosciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a year ago, beating <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of $1.56</a>.
The company reported sales of $627.7 million compared to $515.2 million a year ago, missing the <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/n43544393/neurocrine-biosciences-reports-fourth-quarter-and-fiscal-2024-financial-results-and-provides-finan" rel="noreferrer noopener">consensus of $628.99 million</a>.
Ingrezza fourth quarter and fiscal 2024 net product sales were&nbsp;$615 million&nbsp;and&nbsp;$2.3 billion, respectively.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43273280/neurocrine-obtains-exclusive-rights-for-depression-drug-takeda-reacquires-japan-rights" rel="noreferrer noopener">Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights</a>
Ingrezza fourth-quarter net product sales grew 23% compared to fourth quarter 2023, driven by strong underlying patient demand and improvement in gross-to-net dynamics.
Crenessity fourth quarter and fiscal 2024 net product sales were&nbsp;$2 million, reflecting initial pharmacy orders following FDA approval in&nbsp;December 2024
Guidance: Neurocrine Biosciences expects 2025 Ingrezza Net Product Sales of $2.5 billion-$2.6 billion.
William Blair writes that Ingrezza&#8217;s 2025 revenue guidance is slightly conservative compared to their 2025 estimate of $2.60 billion and the Street estimate of $2.67 billion, which fell below investor expectations.
Analyst Myles Minter writes that near-term pressures are weighing on the Ingrezza trajectory. The analyst continues to view Ingrezza as the gold-standard pharmacotherapy for tardive dyskinesia (TD), given its once-daily dosing, no need for long dose titration intervals, and lack of a suicidality and depression FDA black-box warning.
With Ingrezza still holding 14 years of potential patent protection, William Blair sees a long growth trajectory for the product, but the model addresses near-term competitive pressures ahead of the second-half 2025 salesforce expansion.
William Blair reiterates the <a target="_blank" href="https://www.benzinga.com/quote/NBIX/analyst-ratings" rel="noreferrer noopener">Outperform rating on Neurocrine</a>.
Analyst Reaction:
<ul>
<li>BofA Securities analyst Tazeen Ahmad maintains Neurocrine Biosciences with a Buy and lowers the price target from $184 to $179.</li>
<li>Needham analyst Ami Fadia reiterates the Hold rating.</li>
<li>HC Wainwright analyst Andrew Fein maintains Neurocrine Biosciences with a Buy and lowers the price target from $190 to $185.</li>
</ul>
Price Action: NBIX stock is down 191% at $121.98 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43566749/spire-global-lands-72m-contract-for-canadian-wildfire-detection-stock-jumps" target="_blank" rel="noreferrer noopener">Spire Global Lands ~$50M Contract For Canadian Wildfire Detection; Stock Jumps</a></li>
</ul>

Neurocrine Biosciences shares are trading lower after the company missed its Q4 revenue estimate when reporting financial results. Additionally, HC Wainwright & Co. and B of A Securities lowered their respective price targets on the stock.

Needham analyst Ami Fadia reiterates Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) from Hold to Hold.

Needham Reiterates Hold on Neurocrine Biosciencesto Hold

B of A Securities analyst Tazeen Ahmad maintains Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and lowers the price target from $184 to $179.

B of A Securities Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $179

<h3>Gainers</h3>
<ul>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares moved upwards by 67.7% to $0.27 during Friday's pre-market session. The company's market cap stands at $2.3 million. </li>
<li>Doximity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) stock moved upwards by 24.42% to $72.49. The company's market cap stands at $13.5 billion. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Nutriband (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>) stock increased by 16.49% to $7.77. The market value of their outstanding shares is at $86.2 million. </li>
<li>Helius Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) stock rose 15.25% to $0.68. The company's market cap stands at $2.5 million. </li>
<li>FibroBiologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBLG#NASDAQ">FBLG</a>) stock increased by 14.37% to $1.83. The company's market cap stands at $64.4 million. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) stock moved upwards by 8.62% to $0.65. The company's market cap stands at $1.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Fractyl Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GUTS#NASDAQ">GUTS</a>) stock decreased by 24.2% to $1.22 during Friday's pre-market session. The company's market cap stands at $58.6 million. </li>
<li>Neuronetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STIM#NASDAQ">STIM</a>) shares declined by 21.92% to $2.78. The company's market cap stands at $154.7 million. </li>
<li>Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) stock fell 16.55% to $5.5. The market value of their outstanding shares is at $299.2 million. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) stock fell 13.57% to $9.94. The market value of their outstanding shares is at $30.2 million. </li>
<li>Lipella Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) stock fell 12.26% to $4.08. The market value of their outstanding shares is at $4.9 million. </li>
<li>Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) stock declined by 11.65% to $132.98. The market value of their outstanding shares is at $13.4 billion. As per the press release, Q4 earnings came out yesterday. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FBLG

HSDT

LIPO

NTRB

TNFA

Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) just disclosed its Q4 earnings on Thursday, February 6, 2025 at 04:01 PM.
Here's a brief overview of the earnings report.
<h3>Earnings</h3>
Neurocrine Biosciences missed estimated earnings by -1.0%, reporting an EPS of $1.69 versus an estimate of $1.71.
Revenue was up $112.50 million from the same period last year.
<h3>Overview of Past Earnings</h3>
During the previous quarter, the company beat on EPS by $0.3, leading to a 3.0% drop share price change the next day.
Here's a look at Neurocrine Biosciences's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.51</td>
<td>1.03</td>
<td>1.01</td>
<td>1.15</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.81</td>
<td>1.63</td>
<td>1.20</td>
<td>1.54</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>600.63M</td>
<td>547.07M</td>
<td>511.97M</td>
<td>518.13M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>622.10M</td>
<td>590.20M</td>
<td>515.30M</td>
<td>515.20M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Neurocrine Biosciences <a href="https://www.benzinga.com/quote/NBIX/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Summary: Neurocrine Biosciences Q4

Neurocrine Biosciences Sees INGREZZA FY25 Net Product Sales $2.5B-$2.6B

Press Releases

Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism

Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism

Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device

Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)

Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults

Comments

Neurocrine Biosciences

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga